The global heart failure therapeutics market revenue was around US$ 22.06 billion in 2022 and is estimated to reach US$ 49.6 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.43% during the forecast period from 2023 to 2031.
Heart failure therapeutics are medical treatments and interventions that try to improve and manage the condition of people who have heart failure. Heart failure is a chronic circulatory disorder in which the heart is unable to properly pump blood to fulfill the needs of the body, resulting in a variety of problems and symptoms. It is a serious disorder that necessitates continued medical therapy to enhance the patient's quality of life and slow the disease's progression.
Market Driving Factors
The increasing prevalence of heart failure propels the market growth. According to the American Heart Association, an expected 6.2 million Americans aged 20 and older have heart failure. This number is projected to grow by 46% by 2030, resulting in more than 8 million persons with heart failure.
The surge in focus on healthcare boosts the market growth. Governments all around the world have raised their healthcare spending in recent years. This raised allocation of resources towards healthcare, connected with the increasing awareness about heart failure and its management, has created a conducive environment for market expansion.
Advancements in medical research and technology boost the market growth. Breakthroughs in proteomics, genomics, and metabolomics have opened up new avenues for understanding the pathophysiology of heart failure. This understanding has led to the development of novel drugs and therapeutic techniques that promise enhanced outcomes for patients. For instance, drugs like Sacubitril-Valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI), have revealed superior efficacy in lowering hospitalization and mortality rates compared to traditional treatments.
High development prices may restrain market growth.
Regional Analysis
North America dominated the market in terms of revenue over the forecast period. This can be attributed to the high prevalence rate of cardiovascular diseases (CVDs) along with the advent of the latest technologies such as wearable devices launched by key players in the market.
Prominent Companies
Segmentation Outline
The global heart failure therapeutics market segmentation focuses on Treatment, Type, Stage, End User, and Region.
By Treatment
By Type
By Stage
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL HEART FAILURE THERAPEUTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: HEART FAILURE THERAPEUTICS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL HEART FAILURE THERAPEUTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL HEART FAILURE THERAPEUTICS MARKET, BY TREATMENT
5.1 OVERVIEW
5.2 MEDICAL DEVICES
5.3 MEDICINES
5.4 SURGERY
6 GLOBAL HEART FAILURE THERAPEUTICS MARKET, BY TYPE
6.1 OVERVIEW
6.2 DIAGNOSIS
6.3 PROGNOSIS
7 GLOBAL HEART FAILURE THERAPEUTICS MARKET, BY STAGE
7.1 OVERVIEW
7.2 STAGE A
7.3 STAGE B
7.4 STAGE C
7.5 STAGE D
8 GLOBAL HEART FAILURE THERAPEUTICS MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS AND CLINICS
8.3 MEDICAL RESEARCH ORGANIZATION
9 GLOBAL HEART FAILURE THERAPEUTICS MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3.1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL HEART FAILURE THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
10.4 COMPETITIVE DASHBOARD
10.5 PRODUCT MAPPING
10.6 TOP PLAYER POSITIONING, 2022
10.7 COMPETITIVE HEATMAP
10.8 TOP WINNING STRATEGIES
11 COMPANY PROFILES
11.1 ABBOTT LABORATORIES
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.2 ABIOMED INC
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.3 AMGEN INC
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.4 ASTRAZENECA PLC
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.5 BAYER AG
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.6 BECKMAN COULTER, INC
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.7 BERLIN HEART GMBH
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.8. BOSTON SCIENTIFIC CORP
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.9 BRISTOL-MYERS SQUIBB COMPANY
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.10 CARDIOL THERAPEUTICS INC
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.11 GSK PLC
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.12 IMPULSE DYNAMICS
11.12.1 OVERVIEW
11.12.2 FINANCIAL PERFORMANCE
11.12.3 PRODUCT OUTLOOK
11.12.4 KEY DEVELOPMENTS
11.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.13 JARVIK HEART, INC
11.13.1 OVERVIEW
11.13.2 FINANCIAL PERFORMANCE
11.13.3 PRODUCT OUTLOOK
11.13.4 KEY DEVELOPMENTS
11.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.14 JOHNSON & JOHNSON
11.14.1 OVERVIEW
11.14.2 FINANCIAL PERFORMANCE
11.14.3 PRODUCT OUTLOOK
11.14.4 KEY DEVELOPMENTS
11.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.15 LIVANOVA PLC
11.15.1 OVERVIEW
11.15.2 FINANCIAL PERFORMANCE
11.15.3 PRODUCT OUTLOOK
11.15.4 KEY DEVELOPMENTS
11.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.16 MEDTRONIC PLC
11.16.1 OVERVIEW
11.16.2 FINANCIAL PERFORMANCE
11.16.3 PRODUCT OUTLOOK
11.16.4 KEY DEVELOPMENTS
11.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.17 MERCK & CO., INC
11.17.1 OVERVIEW
11.17.2 FINANCIAL PERFORMANCE
11.17.3 PRODUCT OUTLOOK
11.17.4 KEY DEVELOPMENTS
11.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.18 NOVARTIS AG
11.18.1 OVERVIEW
11.18.2 FINANCIAL PERFORMANCE
11.18.3 PRODUCT OUTLOOK
11.18.4 KEY DEVELOPMENTS
11.18.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.19 ORION CORP
11.19.1 OVERVIEW
11.19.2 FINANCIAL PERFORMANCE
11.19.3 PRODUCT OUTLOOK
11.19.4 KEY DEVELOPMENTS
11.19.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.20 PFIZER INC
11.20.1 OVERVIEW
11.20.2 FINANCIAL PERFORMANCE
11.20.3 PRODUCT OUTLOOK
11.20.4 KEY DEVELOPMENTS
11.20.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.21 ROCHE LTD
11.21.1 OVERVIEW
11.21.2 FINANCIAL PERFORMANCE
11.21.3 PRODUCT OUTLOOK
11.21.4 KEY DEVELOPMENTS
11.21.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved